Virus inoculation of the respiratory tract results in production of local secretory immunoglobulin A (IgA), IgG (2, 21) , and, sometimes, trace amounts of IgM (7, 18) IgG accumulation with few IgM-containing cells and a somewhat later IgA accumulation (6) . Local cellular accumulation has been documented as early as day 2 postinfection (6), and local specific antibody has been detected by day 3 (5) . The immunoglobulin class of the early antibody response is not known. It has been shown that free antibody in BAW after day 8 was both IgG and IgA; however, IgA antibodies predominated later (2, 21) . The appearance of antibody in local immune complexes at day 3 postinfection has been shown to be associated with the disruption and desquamation of infected cells, accumulation of polymorphs, and severe bronchial basement membrane damage (3, 4) . In addition, lungs have been shown to be anticomplementary at this time (9) . There is no convincing data to show that secretory IgA can evoke such tissue-damaging responses or activate the complement bypass mechanism in vivo. It thus seemed likely that the early local antibody would be predominantly IgG, which could mediate what appears to be a local type III immunological reaction.
The studies reported in this paper set out to determine the immunoglobulin class of the earliest detectable specific antibody after respiratory virus infection and to document the subsequent class distribution and the effects of a secondary challenge. A parallel study of systemic virus administration and studies of the effect of viral dose were also undertaken. MATERIALS AND METHODS Experimental design. Six hundred female germfree random-bred Swiss albino mice, weighing 20 to 24 g, were purchased from Charles Rivers Ltd., Mon- 
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CHARLTON AND BLANDFORD treal, Canada. Three hundred mice were infected with live Sendai virus intranasally (i.n.) (5) , and 300 were infected intraperitoneally (i.p. Antibody levels after i.p. 104 TCIID5 (Fig.   2 ). (i) Primary response. IgG and IgM antibodies were first detected simultaneously in the lung, spleen, and serum on day 6. The serum levels of antibody were several times higher than those after 105 and 103 TCID50 of virus. The 10 TCID50 was the only dose in which the spleen cell response was clearly greater than the lung cell response when the different dilution factors were taken into account.
(ii) Secondary response. Secondary antibody responses were detected in all locations at day 41 and were most marked in lungs, spleen, and serum. The secondary response peaked earlier in the spleen than in the lungs or serum. IgA antibody was detected in the serum and spleen lysates. The level of IgA antibody in the serum was five times higher than that observed after 105 TCID5o.
Hemagglutination inhibition antibody response. Hemagglutination inhibition antibody titers in serum after i.n. and i.p. challenges are depicted in the graphs superimposed on the serum histograms in Fig. 1 and 2 (Fig. 3 and 4) . Much higher ratios were observed in BAW than in serum after both i.n. and i.p. challenge. These observations suggest that local manufacture, concentration, or selective secretion was occurring. DISCUSSION Germfree mice were used in these experiments, as a stock of normal Sendai-free mice was unavailable. Intraperitoneal challenge did not result in any apparent lung infection, whereas i.n.-challenged animals had pathological and serum hemagglutination inhibition antibody responses essentially similar to those reported in normal Sendai-free mice (5, 16) . A few fatalities occurred in the 105 and 1O0 TCIDro ranges, which did not occur in normal animals. The 10 TCID50 primary infection was characterized by the most severe and extensive lung damage, with alveolar infection. This may be attributed to efficient and maxmal infectious virus production, whereas the production of incomplete, noninfectious virus probably followed 10i TCID50.
Previous studies (5) have shown that antigenantibody complexes were present in infected Jill] I mouse lungs as early as 3 days post-Sendai infection, associated with submucosal immunoglobulin-containing cells. The failure to detect specific antibody in lung cell lysates before day 6 may be due to excess viral antigen from lysed infected mucosal cells combining with antibody released from lysed plasma cells.
The earliest local antibody detected after infection was IgG, followed by IgM and, lastly, IgA. The appearance of IgG before IgM has also been demonstrated in normal mice following Sendai virus infection (unpublished data). A similarly delayed appearance of IgA antibody followed nonlethal influenza A infection in normal mice (18) . In contrast, some reports on infections in humans indicate that local IgA antibodies may appear exclusively (21) . The discrepancy may be related to the sensitivity of the methodology we have used to detect immunoglobulin class-specific antibodies.
The (1, 20) . In these studies the subjects were not germfree, and it is therefore possible that the local IgA response after systemic challenge may have been the result of stimulating an immunologically experienced secretory surface.
The most impressive difference between i.n. and i.p. infection clearly involved the lack of appearance of IgA antibodies in lung cell lysates and BAW following i.p. virus challenge. It should be emphasized that these findings are in germfree mice and cannot readily be extrapolated to normal mice or humans.
The calculations of RIA antibody-immunoglobulin ratios in serum and BAW showed that the latter were higher than the former at all times, regardless of the route of challenge. This would indicate that, although serum exudation certainly occurred with acute inflammation, as indicated by the BAW immunoglobulin concentrations, either a local antibody-concentrating mechanism, selective secretion of antibody into the respiratory fluid, or local manufacture must also have occurred. The presence of IgA antibody in secretions and its total absence from serum after i.n. challenge clearly support local manufacture and secretion, a conclusion further supported by the presence of IgA antibody-producing cells in the lungs. 
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